Arab Maliheh, Jamdar Farzaneh, Sadat Hosseini Maryam, Ghodssi- Ghasemabadi Robabe, Farzaneh Farah, Ashrafganjoei Tahereh
Cancer Research Center, ShahidBeheshti University of Medical Science, Tehran, Iran. Email:
Asian Pac J Cancer Prev. 2018 May 26;19(5):1319-1324. doi: 10.22034/APJCP.2018.19.5.1319.
Background: Primary cytoreduction surgery followed by chemotherapy is the cornerstone treatment for epithelial ovarian cancer (EOC). In patients with a low probability of optimal primary surgical debulking, neoadjuvant chemotherapy (NACT) followed by interval debulking increases the chance of optimal surgery. The aim of this study was to develop a model to identify preoperative predictors for suboptimal cytoreduction. Methods: Medical records of patients with EOC who underwent primary cytoreductive surgery in a referral tertiary gyneco-oncology center were reviewed from 2007 to 2017. Data were collected on a range of characteristics including demographic features, comorbidities, serum tumor markers, hematologic markers, preoperative imaging, surgical procedures, and pathologic reports. Univariate and multivariate analyses were performed to clarify the ability of preoperative factors to predict suboptimal primary surgery. Results: The majority of patients (71.3%) who underwent primary cytoreductive surgery were optimally debulked. Based on the Youden index, the best cut-off point for the serum CA125 level to distinguish suboptimal debulking was 420U/ml with 0.730 (95%CI:0.559 to 0.862) sensitivity and 0.783 (0.684 to 0.862) specificity. Multiple logistic regression results showed that serum CA125 level >420 U/ ml (p value <0.001), the presence of liver metastasis on preoperative imaging (p value: 0.041) and ascites (p value: 0.032) or massive ascites (p value:0.010) significantly increased the risk of suboptimal debulking (logit p = 2.36 CA125 level +1.85 Liverinvolvement +1.68 presence of Ascites+ 2.28 Massive Ascites). Conclusion:The present study suggests that a serum CA125 level >420 U/ml, the presence of ascites or massive ascites and liver metastasis are strong predictors of suboptimal primary surgery in cases of EOC. Based on the constructed model, with any of these 4 factors, the probability of suboptimal debulking in EOC is more than 80%.
原发性细胞减灭术联合化疗是上皮性卵巢癌(EOC)的基石性治疗方法。对于原发性手术达到最佳减瘤效果可能性较低的患者,新辅助化疗(NACT)后行间隔期减瘤术可增加实现最佳手术效果的机会。本研究的目的是建立一个模型来识别次优细胞减灭术的术前预测指标。方法:回顾了2007年至2017年在一家三级转诊妇科肿瘤中心接受原发性细胞减灭术的EOC患者的病历。收集了一系列特征的数据,包括人口统计学特征、合并症、血清肿瘤标志物、血液学标志物、术前影像学检查、手术操作和病理报告。进行单因素和多因素分析以阐明术前因素预测次优原发性手术的能力。结果:大多数接受原发性细胞减灭术的患者(71.3%)实现了最佳减瘤。根据约登指数,血清CA125水平区分次优减瘤的最佳截断点为420U/ml,敏感性为0.730(95%CI:0.559至0.862),特异性为0.783(0.684至0.862)。多因素逻辑回归结果显示,血清CA125水平>420 U/ml(p值<0.001)、术前影像学检查发现肝转移(p值:0.041)以及腹水(p值:0.032)或大量腹水(p值:0.010)显著增加了次优减瘤的风险(逻辑回归系数p = 2.36×CA125水平 +1.85×肝转移 +1.68×腹水存在 + 2.28×大量腹水)。结论:本研究表明,血清CA125水平>420 U/ml、存在腹水或大量腹水以及肝转移是EOC患者次优原发性手术的有力预测指标。基于构建的模型,具备这4个因素中的任何一个,EOC患者次优减瘤的概率超过80%。